ASC36

Beyond's analysis on ASC36

• 2026-09-08 — Ascletis transitions to oral delivery for obesity treatment with US Phase I trial initiation of ASC36

Recent news mentioning ASC36

• 2026-10-02 — Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
• 2026-10-02 — Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
• 2026-09-08 — Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

Browse the full archive →